Evommune, Inc. (EVMN)

Evommune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-75.99	-68.87	-66.81	-34.05
Depreciation & Amortization	1.36	1.39	1.29	1
Stock-Based Compensation	8.77	5.86	1.72	1.48
Other Adjustments	-11.19	-10.7	-1.82	-1.75
Changes in Accounts Payable	-2.29	-0.84	6.51	0.13
Changes in Accrued Expenses	-1.59	2.82	2.7	1.19
Changes in Unearned Revenue	-1.5	-3	-	3
Changes in Other Operating Activities	-0.46	-3.1	-1.79	-0.97
Operating Cash Flow	-80.05	-76.44	-58.2	-29.97
Capital Expenditures	-0.32	-0.24	-0.09	-0.12
Purchases of Investments	-147.55	-199.17	-90.26	-91.31
Proceeds from Sale of Investments	54.25	84.1	86.35	43
Investing Cash Flow	-93.62	-115.31	-3.99	-48.43
Issuance of Common Stock	0	157.29	0.01	0.01
Net Common Stock Issued (Repurchased)	0	157.29	0.01	0.01
Issuance of Preferred Stock	32.61	65.23	49.83	63.98
Net Preferred Stock Issued (Repurchased)	32.61	65.23	49.83	63.98
Other Financing Activities	116.23	-1.76	-0.42	-0.23
Financing Cash Flow	338.03	220.76	49.42	63.75
Net Cash Flow	43.82	29.02	-12.77	-14.65
Free Cash Flow	-80.36	-76.68	-58.28	-30.09
FCF Margin	-803.63%	-589.82%	-832.61%	-601.76%
Free Cash Flow Per Share	-5.69	-12.49	-38.64	-24.01
Levered Free Cash Flow	-81.28	-71.84	-59.69	-29.83
Unlevered Free Cash Flow	-94.79	-84.04	-61.39	-33.62

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q